Related references
Note: Only part of the references are listed.Reversible Dimerization of Human Serum Albumin
Alexey Chubarov et al.
MOLECULES (2021)
A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs
Ying Huang et al.
BIOORGANIC CHEMISTRY (2020)
Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin
Nayelli Guadalupe Teran-Saavedra et al.
MOLECULES (2020)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
Lee D. Cranmer
ONCOTARGETS AND THERAPY (2019)
The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies
K. C. Nicolaou et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Synthesis and Evaluation of Camptothecin Antibody-Drug Conjugates
Wei Li et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Thiophene Derivatives as Anticancer Agents and Their Delivery to Tumor Cells Using Albumin Nanoparticles
Guangsheng Cai et al.
MOLECULES (2019)
New Insights About Albumin and Liver Disease
Joana R. Carvalho et al.
ANNALS OF HEPATOLOGY (2018)
Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
Jincheng Yang et al.
DRUG DELIVERY (2018)
Applications of stimuli-responsive nanoscale drug delivery systems in translational research
Mengjie Gu et al.
DRUG DISCOVERY TODAY (2018)
Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches
Ritu R. Kudarha et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2017)
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Natalia Baran et al.
CLINICAL CANCER RESEARCH (2017)
The targeted delivery of the c-Src peptide complexed with schizophyllan to macrophages inhibits polymicrobial sepsis and ulcerative colitis in mice
Ye-Ram Kim et al.
BIOMATERIALS (2016)
The Warburg Effect: How Does it Benefit Cancer Cells?
Maria V. Liberti et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery
Jonathan G. Mehtala et al.
BIOCONJUGATE CHEMISTRY (2015)
Classification of stimuli-responsive polymers as anticancer drug delivery systems
Bita Taghizadeh et al.
DRUG DELIVERY (2015)
Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin
Thibaut Legigan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B
Andre Warnecke et al.
ARCHIV DER PHARMAZIE (2007)
Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy
Bjoern Schmid et al.
BIOCONJUGATE CHEMISTRY (2007)
Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)
Da-Eun Chung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors
MN Wente et al.
INVESTIGATIONAL NEW DRUGS (2005)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan
CF Verschraegen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities
G Saito et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Share Paper
